Denise Garcia1, Patrick Nasarre1, Ingrid V Bonilla1, Eleanor Hilliard1, Yuri K Peterson2, Laura Spruill3, Anne-Marie Broome4, Elizabeth G Hill5, Jason T Yustein6, Shikhar Mehrotra1, Nancy Klauber-DeMore7. 1. Department of Surgery, Medical University of South Carolina, Charleston, SC, USA. 2. Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA. 3. Department of Pathology, Medical University of South Carolina, Charleston, SC, USA. 4. Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA. 5. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 6. Department of Pediatrics, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, USA. 7. Department of Surgery, Medical University of South Carolina, Charleston, SC, USA. demore@musc.edu.
Abstract
BACKGROUND: We previously reported that secreted frizzled-related protein-2 (SFRP2) is expressed in a variety of tumors, including sarcoma and breast carcinoma, and stimulates angiogenesis and inhibits tumor apoptosis. Therefore, we hypothesized that a humanized SFRP2 monoclonal antibody (hSFRP2 mAb) would inhibit tumor growth. METHODS: The lead hSFRP2 antibody was tested against a cohort of 22 healthy donors using a time course T-cell assay to determine the relative risk of immunogenicity. To determine hSFRP2 mAb efficacy, nude mice were subcutaneously injected with SVR angiosarcoma cells and treated with hSFRP2 mAb 4 mg/kg intravenously every 3 days for 3 weeks. We then injected Hs578T triple-negative breast cells into the mammary fat pad of nude mice and treated for 40 days. Control mice received an immunoglobulin (Ig) G1 control. The SVR and Hs578T tumors were then stained using a TUNEL assay to detect apoptosis. RESULTS: Immunogenicity testing of hSFRP2 mAb did not induce proliferative responses using a simulation index (SI) ≥ 2.0 (p < 0.05) threshold in any of the healthy donors. SVR angiosarcoma tumor growth was inhibited in vivo, evidenced by significant tumor volume reduction in the hSFRP2 mAb-treated group, compared with controls (n = 10, p < 0.001). Likewise, Hs578T triple-negative breast tumors were smaller in the hSFRP2 mAb-treated group compared with controls (n = 10, p < 0.001). The hSFRP2 mAb treatment correlated with an increase in tumor cell apoptosis (n = 11, p < 0.05). Importantly, hSFRP2 mAb treatment was not associated with any weight loss or lethargy. CONCLUSION: We present a novel hSFRP2 mAb with therapeutic potential in breast cancer and sarcoma that has no effect on immunogenicity.
BACKGROUND: We previously reported that secreted frizzled-related protein-2 (SFRP2) is expressed in a variety of tumors, including sarcoma and breast carcinoma, and stimulates angiogenesis and inhibits tumor apoptosis. Therefore, we hypothesized that a humanized SFRP2 monoclonal antibody (hSFRP2 mAb) would inhibit tumor growth. METHODS: The lead hSFRP2 antibody was tested against a cohort of 22 healthy donors using a time course T-cell assay to determine the relative risk of immunogenicity. To determine hSFRP2 mAb efficacy, nude mice were subcutaneously injected with SVR angiosarcoma cells and treated with hSFRP2 mAb 4 mg/kg intravenously every 3 days for 3 weeks. We then injected Hs578T triple-negative breast cells into the mammary fat pad of nude mice and treated for 40 days. Control mice received an immunoglobulin (Ig) G1 control. The SVR and Hs578T tumors were then stained using a TUNEL assay to detect apoptosis. RESULTS: Immunogenicity testing of hSFRP2 mAb did not induce proliferative responses using a simulation index (SI) ≥ 2.0 (p < 0.05) threshold in any of the healthy donors. SVR angiosarcoma tumor growth was inhibited in vivo, evidenced by significant tumor volume reduction in the hSFRP2 mAb-treated group, compared with controls (n = 10, p < 0.001). Likewise, Hs578T triple-negative breast tumors were smaller in the hSFRP2 mAb-treated group compared with controls (n = 10, p < 0.001). The hSFRP2 mAb treatment correlated with an increase in tumor cell apoptosis (n = 11, p < 0.05). Importantly, hSFRP2 mAb treatment was not associated with any weight loss or lethargy. CONCLUSION: We present a novel hSFRP2 mAb with therapeutic potential in breast cancer and sarcoma that has no effect on immunogenicity.
Authors: J L Arbiser; M A Moses; C A Fernandez; N Ghiso; Y Cao; N Klauber; D Frank; M Brownlee; E Flynn; S Parangi; H R Byers; J Folkman Journal: Proc Natl Acad Sci U S A Date: 1997-02-04 Impact factor: 11.205
Authors: Andrew Courtwright; Sharareh Siamakpour-Reihani; Jack L Arbiser; Natalie Banet; Eleanor Hilliard; Levi Fried; Chad Livasy; David Ketelsen; Desh Bandhu Nepal; Charles M Perou; Cam Patterson; Nancy Klauber-Demore Journal: Cancer Res Date: 2009-05-19 Impact factor: 12.701
Authors: Sharareh Siamakpour-Reihani; Joseph Caster; Desh Bandhu Nepal; Andrew Courtwright; Eleanor Hilliard; Jerry Usary; David Ketelsen; David Darr; Xiang Jun Shen; Cam Patterson; Nancy Klauber-Demore Journal: PLoS One Date: 2011-06-03 Impact factor: 3.240
Authors: Muhammad Riaz; Marijn T M van Jaarsveld; Antoinette Hollestelle; Wendy J C Prager-van der Smissen; Anouk A J Heine; Antonius W M Boersma; Jingjing Liu; Jean Helmijr; Bahar Ozturk; Marcel Smid; Erik A Wiemer; John A Foekens; John W M Martens Journal: Breast Cancer Res Date: 2013-04-19 Impact factor: 6.466
Authors: Maria Tabuso; Raghu Adya; Richard Stark; Kishore Gopalakrishnan; Yee Wah Tsang; Sean James; Andrew White; Adrian Fisk; Federica Dimitri; Mark Christian; Ramesh Pulendran Arasaradnam Journal: Int J Mol Sci Date: 2021-02-28 Impact factor: 5.923
Authors: Patrick Nasarre; Denise I Garcia; Julie B Siegel; Ingrid V Bonilla; Rupak Mukherjee; Eleanor Hilliard; Paramita Chakraborty; Cécile Nasarre; Jason T Yustein; Margaret Lang; Aneese A Jaffa; Shikhar Mehrotra; Nancy Klauber-DeMore Journal: Cancers (Basel) Date: 2021-05-30 Impact factor: 6.639